论文部分内容阅读
以急性、陈旧性心肌梗塞作为冠心病研究对象。处理组３８例静滴川芎嗪每日１６０ｍｇ，疗程１０天，测定其治疗前、后血脂质过氧化物（ＬＰＯ）分别为８．４４±２．７８ｎｍｏｌ／ｍｌ，４．１３±１．２４ｎｍｏｌ／ｍｌ；血总超氧化物歧化酶（ＳＯＤ）分别为１４．２１±３．７Ｎｕ／ｍｌ，１９．９８±３．３３Ｎｕ／ｍｌ；血总巯基分别为２８８±７４．１１μｍｏｌ／Ｌ，３８６．２６±６６．０３μｍｏｌ／Ｌ，以上治疗前后均差异有高度显著性（ｐ＜０．０１）．血尿酸治疗前后差异无显著性（ｐ＞０．０５）。川芎嗪可降低血ＬＰＯ、提高ＳＯＤ；升高巯基总量；中止心绞痛，其机理为抗血小板聚集；调节ＴＸＡ２／ＰＧＩ２；多改善心肌缺血，保护心肌细胞膜。
Acute, old myocardial infarction as coronary heart disease research object. Treatment group, 38 cases of intravenous infusion of Ligustrazine 160mg daily for 10 days, measured before and after treatment, blood lipid peroxide (LPO) were 8.44 ± 2.78nmol / ml, 4.13 ± 1.24nmol / ml; the total superoxide dismutase (SOD) was 14.21 ± 3.7Nu / ml and 19.98 ± 3.33Nu / ml respectively; the total thiol groups were 288 ± 74.11μmol / L and 386.26 ± 66.03μmol / L, the difference between before and after the treatment was highly significant (p <0.01). Blood uric acid before and after treatment was no significant difference (p> 0.05). Ligustrazine can reduce blood LPO, increase SOD; increase the total amount of sulfhydryl group; arrest angina pectoris, its mechanism is anti-platelet aggregation; regulate TXA2 / PGI2; improve myocardial ischemia and protect myocardial cell membrane.